Quantcast

Latest Adenoviridae Stories

2011-07-13 09:00:00

Durham, N.C., July 13, 2011 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced that patient dosing has begun in the AdV HALT Trial (A Randomized, Placebo-Controlled, Multi-site Phase 2 Study Evaluating the Safety and Efficacy of Preemptive Treatment with CMX001 for the Prevention of Adenovirus Disease Following Hematopoietic Stem Cell Transplantation [HSCT]).The company also announced that the U.S.

2011-06-27 23:12:24

Novel tools and methods for delivering therapeutic genes to cells in the central nervous system hold great promise for the development of new treatments to combat incurable neurologic diseases.

2011-05-11 12:46:00

DURHAM, N.C., May 11, 2011 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing oral antiviral therapeutics, today presented data showing that the majority of immunocompromised patients with severe adenovirus infections who were treated with Chimerix's lead antiviral compound, CMX001, had a > 99% decrease in viral load compared to baseline after two weeks of therapy.

2011-04-02 01:52:43

Early data from phase I trials of an HCV vaccine presented today at the International Liver CongressTM show encouraging results, with high immunogenicity and good safety profile.

2011-03-25 08:24:00

DURHAM, N.C., March 25, 2011 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics to address life-threatening diseases, announced today that Kenneth I.

2011-03-01 08:00:00

DURHAM, N.C., March 1, 2011 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics to address life-threatening diseases, announced today that Kenneth I.

2011-02-24 07:30:00

DURHAM, N.C., Feb. 24, 2011 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company advancing orally-available antiviral therapeutics to address life-threatening diseases, announced today that Kenneth I.

2011-02-14 07:30:00

DURHAM, N.C., Feb. 14, 2011 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available broad spectrum antiviral therapeutics, today announced the completion of a $45 million Series F financing.

2011-01-24 04:42:00

ORLANDO, Florida, January 24, 2011 /PRNewswire/ -- The Canine VacciCheck was discussed during a panel discussion in a vaccination symposium at the NAVC. During this panel discussion, a question was raised as to the options available regarding checking for titers for the core vaccines of Hepatitis, Parvovirus and Distemper. Professor Ronald Schultz from the University of Wisconsin mentioned the Canine VacciCheck as a novel "in house" option for titer checking.


Latest Adenoviridae Reference Libraries

0_f9fe10c6664d20ba0d9091907b66a65f
2011-01-05 16:00:36

Human parainfluenza viruses, belonging to the paramyxovirus family, are a group of four distinct serotypes of enveloped single-stranded RNA viruses. They are the second most common cause of lower respiratory tract infection in younger children. Many times the host has repeat infections throughout life with symptoms that may include upper respiratory tract illness or more commonly, a cold and sore throat. It can also cause severe pneumonia in immunosuppressed people. There is currently no...

More Articles (1 articles) »
Word of the Day
whirret
  • To give a box on the ear to.
The word 'whirret' may be onomatopoeic.